Dyne Therapeutics Financials - Benzinga

Dyne Therapeutics Inc

DYNNASDAQ

Trade with Public

Trade with Public

$16.48

0.271.7%

마지막 업데이트: Sep 30, 10:21 AM

개요 뉴스 실적 전망 이벤트 목표가재무심리 지분 현황 비교 옵션 주식 보고서

Dyne Therapeutics Financials

Dyne Therapeutics (DYN) financial statements — income, revenue, gross margin and key metrics.

Earnings & Guidance News

PRO
Dyne Therapeutics Q2 EPS $(1.08) Misses $(0.75) Estimate

Dyne Therapeutics (NASDAQ:DYN) reported quarterly losses of $(1.08) per share which missed the analyst consensus estimate of $(0.75) by 44 percent. This is a 11.34 percent decrease over losses of $(0.97) per share from

Benzinga Newsdesk

PRO
Dyne Therapeutics Q1 EPS $(0.73) Beats $(0.78) Estimate

Dyne Therapeutics (NASDAQ:DYN) reported quarterly losses of $(0.73) per share which beat the analyst consensus estimate of $(0.78) by 6.41 percent. This is a 30.48 percent increase over losses of $(1.05) per share from

Benzinga Newsdesk

PRO
Dyne Therapeutics Q4 EPS $(0.76) Beats $(0.79) Estimate

Dyne Therapeutics (NASDAQ:DYN) reported quarterly losses of $(0.76) per share which beat the analyst consensus estimate of $(0.79) by 3.18 percent. This is a 13.64 percent increase over losses of $(0.88) per share from

Benzinga Newsdesk

Sarepta CEO To Jump Ship After 'Tumultuous' Year

Sarepta stock drops after a wider loss, Elevidys sales fall 33%, and CEO retirement plans add fresh uncertainty for investors.

Vandana Singh

PRO
Dyne Therapeutics Q3 EPS $(0.76) Beats $(0.85) Estimate

Dyne Therapeutics (NASDAQ:DYN) reported quarterly losses of $(0.76) per share which beat the analyst consensus estimate of $(0.85) by 11.01 percent. This is a 20.83 percent increase over losses of $(0.96) per share from

Benzinga Newsdesk

These Analysts Lower Their Forecasts On Dyne Therapeutics Following Q2 Loss

Avi Kapoor

© 2026 Benzinga | All Rights Reserved